|
|
 |
|
Viewing report
|
|
|
|
U.S. Point-of-care Testing Markets
Frost & Sullivan, March 2010, Pages: 198
This research service analyzes the market for point-of-care testing within the United States. The market is divided into 13 segments and covers testing performed by healthcare professionals in the physician office lab, hospital, clinics, and patient self-testing environments. Each segment covers the market overview, competitive structure, market share analysis, revenue forecasts, and market trends. The key challenges and strategies are covered for the total market overview. In this study, tests performed at the point-of-care are defined as those completed within a close proximity to patients but outside a central laboratory. Products marketed as over the counter where consumers can purchase at retail outlets are excluded.
This Frost & Sullivan research service titled U.S. Point-of-care Testing Markets provides challenges facing point-of-care testing (POCT) manufacturers and recommendations for overcoming growing competition and other limitations. In this research, Frost & Sullivan's expert analysts thoroughly examine the following market sectors: glucose POCT, glycated haemoglobin (HbA1C) POCT, cholesterol POCT, blood gas and electrolyte POCT, drugs of abuse POCT, infectious disease POCT, pregnancy POCT, hematology POCT, coagulation activated clotting time (ACT)/ activated partial thromboplastin time (APTT) POCT, coagulation prothrombin time (PT) POCT, cardiac biomarkers POCT, fecal occult blood testing, and urinalysis POCT.
This analysis is available through Frost & Sullivan's Drug Discovery & Clinical Diagnostics Growth Partnership Service program. With continuous access to intelligence and resources from all seven perspectives of the Complex Business Universe, the Growth Partnership Services program ensures that you and your Growth Team™ are able to maintain a 360 Degree Perspective of the market. This comprehensive, objective information allows your company to mitigate risk, identify new opportunities, and drive effective strategies for growth.
Market Overview
New Opportunities in the U.S. POCT Market Prompt a Change of Business Strategies among Participants
Companies in the POCT space have responded aggressively to the changes in the competitive landscape and growing end-user needs by expanding their product lines and test capabilities. They have a plethora of opportunities, as testing is finding increasing applications in new environments such as patient homes and novel disease areas. This proliferation of testing is expected to not only drive test use and compliance, but also create additional revenue streams such as patient services and monitoring. While the infectious disease segment has benefited from the rise in infections and detection of new diseases and mutations, the coagulation monitoring segment has grown dramatically due to increased testing in patient homes and the growth of patient services. “To continue to penetrate the larger in-vitro diagnostics market, manufacturers must demonstrate the value of their products to healthcare professionals to encourage them to change their current testing practices,” says the analyst of this research. “The ability of companies to persuade healthcare professionals to move away from alternative testing methods such as central laboratory testing or directly competing POC tests will determine their success.”
However, it is difficult to alter established testing methods in settings such as hospitals and physicians’ office labs. POCT adoption depends not only on suppliers’ ability to provide better test capability and accuracy than alternate methods, but also a clear definition of overall test utility in improving patient outcomes. Once this utility is established, brand recognition, marketing, and distribution strategies will play a significant role in determining product-specific adoption. POCT companies can establish the superiority of their products over competing methods through convincing clinical trials, relevant certifications, and support from health advocate groups such as the American Heart Association (AHA). Leveraging these benefits, companies must work to establish robust relationships with end users and distributors. This will enhance brand recognition and ensure that end users gain the best value from their products and solutions.
“Owing to the critical nature of many POC tests, the ability to exhibit data reliability and accuracy will continually dictate product adoption,” notes the analyst. “The ability of manufacturers to demonstrate product advantages over competing methods and successful promotions through sales channels will largely determine product acceptance and in turn, company market share.”
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Glucose POCT
- HbA1C POCT
- Cholesterol POCT
- Blood gas and electrolyte POCT
- Drugs of abuse POCT
- Infectious disease POCT
- Pregnancy POCT
- Hematology POCT
- Coagulation ACT/APTT POCT
- Coagulation PT POCT
- Cardiac biomarkers POCT
- Fecal occult blood testing
- Urinalysis POCT
- Technologies
The following technologies are covered in this research:
- Immunoassays
- Molecular diagnostics
- Lateral flow assays
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Point of Care Diagnostic Testing World Markets
European Point of Care Testing Market
Point of Care Diagnostic Testing Sector Trends
European Point of Care Diagnostic Testing Markets
European Coagulation Diagnostics Markets
Point of Care Testing: Evaluating the Return to Evidence Based Medicine, Novel Technologies and the Competitive Landscape
Point of Care Diagnostics: Players, products & future market prospects
In-vitro Diagnostics Market Outlook in Australia
Coagulation Self-Testing: Devices, Markets, Players and Prospects
In-vitro Diagnostics Market Outlook in Taiwan
|
|
|
|
